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The systematic collection of behavioural information 
is an important component of second-generation HIV 
surveillance. The extent of behavioural surveillance 
among injecting drug users (IDUs) in Europe was exam-
ined using data collected through a questionnaire sent 
to all 31 countries of the European Union and European 
Free Trade Association as part of a European-wide 
behavioural surveillance mapping study on HIV and 
other sexually transmitted infections. The question-
naire was returned by 28 countries during August to 
September 2008: 16 reported behavioural surveil-
lance studies (two provided no further details). A total 
of 12 countries used repeated surveys for behavioural 
surveillance and five used their Treatment Demand 
Indicator system (three used both approaches). The 
data collected focused on drug use, injecting prac-
tices, testing for HIV and hepatitis C virus and access 
to healthcare. Eight countries had set national indica-
tors: three indicators were each reported by five coun-
tries: the sharing any injecting equipment, uptake 
of HIV testing and uptake of hepatitis C virus test-
ing. The recall periods used varied. Seven countries 
reported conducting one-off behavioural surveys (in 
one country without a repeated survey, these resulted 
an informal surveillance structure). All countries used 
convenience sampling, with service-based recruitment 
being the most common approach. Four countries had 
used respondent-driven sampling. Three fifths of the 
countries responding (18/28) reported behavioural 
surveillance activities among IDUs; however, har-
monisation of behavioural surveillance indicators is 
needed.
Introduction 
Injecting	 drug	 users	 (IDUs)	 are	 vulnerable	 to	 a	 wide	
range	 of	 viral	 and	 bacterial	 infections	 through	 poor	
injection	hygiene	[1-3].	These	infections,	which	include	
HIV,	hepatitis	C	and	hepatitis	B,	result	in	considerable	
levels	 of	 morbidity	 and	 mortality.	 With	 an	 estimated	
750,000	to	1	million	active	IDUs	in	the	European	Union	
(EU)	 [4],	 these	 infections	have	the	potential	 to	place	a	
considerable	burden	on	European	healthcare	systems,	
as	 well	 as	 adversely	 impacting	 on	 the	 well-being	 of	
those	who	inject	drugs.
Interventions	 have	 been	 adopted	 throughout	 Europe	
that	 aim	 to	 reduce	 risk	 of	 these	 infections	 [5];	 these	
interventions	include	opiate	substitution	therapy	(OST)	
and	needle	and	syringe	exchange	programmes	(NSPs),	
both	of	which	have	been	shown	to	effective	in	prevent-
ing	 infections	 [6-10].	 They	aim	 to	 reduce	 infections	by	
changing	 the	behaviours	 that	place	 individuals	at	 risk	
of	infection,	such	as	through	reducing	the	sharing	and	
reuse	of	injecting	equipment	and	by	decreasing	the	fre-
quency	of	drug	injection.	Monitoring	the	levels	of	these	
behaviours	is	thus	important	for	assessing	the	impact	
of	intervention	programmes	[11].	The	systematic	collec-
tion	 of	 information	 on	 risk	 and	 protective	 behaviours	
is	 therefore	 an	 important	 part	 of	 second-generation	
HIV	surveillance	systems	[12].	Behavioural	surveillance	
focused	on	IDUs	often	looks	at	behaviours	related	to	a	
range	of	viral	infections	of	the	blood,	not	just	HIV,	due	
to	the	similarities	in	the	routes	of	transmission	[13].	
In	 response	 to	 the	 HIV	 epidemic,	 some	 countries	
in	 Europe	 established	 studies	 to	 monitor	 HIV	 and/
or	 related	 risk	 behaviours	 among	 IDUs	 [14,15].	 The	
high	burden	due	 to	 infections	among	 IDUs	 resulted	 in	
the	 European	 Monitoring	 Centre	 for	 Drugs	 and	 Drug	
Addiction	 (EMCCDA)	 developing	 its	 drug-related	 infec-
tious	disease	key	indicator	[13].	This	indicator	has	col-
lected	 data	 on	 the	 prevalence	 of	 HIV	 and	 hepatitis	 B	
and	C	since	the	late	1990s,	and	more	recently	has	col-
lated	behavioural	data.	
We	 examine	 here	 the	 extent	 of	 behavioural	 surveil-
lance	 among	 IDUs	 in	 the	 EU	 Member	 States	 and	
European	 Free	 Trade	 Association	 (EFTA)	 countries	 is	
examined,	focusing	on	the	methods	employed	and	the	
indicators	 used.	 The	 EU/EFTA	 countries	 are	 Austria,	
Belgium,	 Bulgaria,	 Cyprus,	 Czech	 Republic,	 Denmark,	
Estonia,	 Finland,	 France,	 Germany,	 Greece,	 Hungary,	
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Iceland,	Ireland,	Italy,	Latvia,	Liechtenstein,	Lithuania,	
Luxembourg,	 Malta,	 Netherlands,	 Norway,	 Poland,	
Portugal,	Romania,	Slovakia,	Slovenia,	Spain,	Sweden,	
Switzerland	and	the	United	Kingdom.
Methods 
During	 August	 and	 September	 2008,	 a	 survey	 was	
undertaken	 of	 all	 EU	 Member	 States	 and	 EFTA	 coun-
tries	 about	 behavioural	 surveillance	 activities	 related	
to	HIV	and	other	sexually	transmitted	infections	(STIs)..	
Each	 country	 was	 sent	 nine	 separate	 questionnaires	
[16,17].	 One	 explored	 the	 overall	 national	 system	 for	
behavioural	 surveillance	 and	 second-generation	 HIV	
surveillance.	The	remaining	eight	questionnaires	each	
asked	about	a	specific	subpopulation	(general	popula-
tion,	youth,	men	who	have	sex	with	men	(MSM),	IDUs,	
STI	clinic	attendees,	migrants,	sex	workers	and	people	
living	with	HIV/AIDS).	It	was	emphasised	on	each	ques-
tionnaire	 that	 the	 focus	 was	 behavioural	 data	 collec-
tion,	as	opposed	to	biological	surveillance.
The	 population-specific	 questionnaires	 identified	
whether	 a	 country	 had	 undertaken	 behavioural	 sur-
veillance	activities	for	that	population	and	if	so,	asked	
them	 to	 provide	 information	 about	 the	 methodology	
used.	 In	 particular,	more	 details	 were	 requested	with	
respect	 to	 the	 year(s)	 in	 which	 behavioural	 studies	
had	been	performed	(since	1985),	sample	sizes,	target	
populations,	 geographical	 coverage,	 and	 the	 recruit-
ment	 and	 data	 collection	 methods	 used.	 Information	
was	requested	on:	(i)	all	of	the	repeated	studies	under-
taken,	 that	 is,	 either	 cross-sectional	 behavioural	 sur-
veys	that	have	been	repeated	over	time,	cohort	studies	
and	any	other	repeated	collections	of	behavioural	data	
(referred	to	as	‘behavioural	surveillance	studies’);	and	
(ii)	any	one-off	behavioural	surveys	that	had	been	con-
ducted,	 that	 is,	 surveys	 that	 have	 only	 been	 under-
taken	at	a	single	point	 in	 time	 (referred	 to	as	 ‘one-off	
surveys’).	Respondents	were	asked	to	indicate	the	main	
topics	covered	 in	 the	behavioural	surveillance	studies	
from	a	detailed	list	grouped	as	follows:	knowledge	and	
attitudes	regarding	HIV	and	other	STIs,	sexual	relation-
ships	and	sexual	partners,	sexual	activity	and	lifestyle,	
exposure	to	risk	of	infection,	HIV	and	STI	testing,	drugs	
and	 substance	 use.	 Information	 was	 also	 requested	
on	any	main	 indicators	 that	 the	country	was	currently	
using	for	monitoring	purposes	that	were	based	on	the	
behavioural	surveillance	data.
The	questionnaires	were	sent	by	email	to	people	in	the	
countries	who	were	the	contact	points	 for	HIV	surveil-
lance	 for	 the	 European	 Centre	 for	 Disease	 Prevention	
and	Control	(ECDC),	with	the	option	of	consulting	other	
colleagues	with	 specialist	 knowledge	 to	 complete	 the	
questionnaires.	 In	 the	 case	 of	 the	 IDU	 questionnaire,	
the	 contact	 points	 were	 encouraged	 to	 liaise	 with	
the	 European	 Monitoring	 Centre	 for	 Drugs	 and	 Drug	
Addiction	(EMCDDA)	national	 focal	point.	The	key	con-
tacts	returned	the	completed	questionnaires	and	these	
were	 loaded	 into	a	password-protected	database.	The	
data	 for	 each	 population	 were	 analysed	 separately	
by	 an	 expert	 team	 member	 (listed	 at	 the	 end	 of	 this	
article).	
In	February	2009,	a	draft	mapping	of	behavioural	sur-
veillance	 activities	 was	 presented	 and	 discussed	 at	
the	Behavioural	Surveillance	Expert	Meeting	 that	was	
organised	as	part	 of	 the	project.	A	 total	 of	 50	partici-
pants,	 including	experts	 in	behavioural	surveys	 in	the	
various	populations,	national	experts	and	representa-
tives	 of	 international	 organisations	 –	 EMCDDA,	 the	
World	Health	Organization	 (WHO)	and	the	 Joint	United	
Nations	Programme	on	HIV/AIDS	 (UNAIDS)	–	 reviewed	
the	 mapping	 and	 the	 suggested	 sets	 of	 indicators.	 A	
revised	draft	of	the	mapping	was	sent	to	the	countries	
for	 validation	 and	 11	 provided	 additional	 information	
on	 there	 activities,	 which	 was	 then	 incorporated	 into	
the	final	mapping.
Results 
Of	the	31	countries	invited	to	participate,	28	returned	a	
questionnaire	on	IDUs.	Of	these	28,	18	reported	behav-
ioural	surveillance	activities	among	IDUs:	16	indicated	
that	 they	 had	 one	 or	 more	 behavioural	 surveillance	
studies	and	seven	had	conducted	one-off	surveys.	Five	
countries	 had	 conducted	 both	 types	 of	 studies.	 Thus	
10	of	 the	28	 responding	 countries	 reported	having	no	
behavioural	surveillance	related	activities	among	IDUs.
Behavioural surveillance studies
Of	 the	 16	 countries	 that	 had	 conducted	 one	 or	 more	
behavioural	 surveillance	 studies	 among	 IDUs,	 two	
did	 not	 provide	 further	 details.	 Among	 the	 other	 14	
countries,	 either	 repeated	 surveys	 or	 cohorts	 were	
used	 and/or	 data	were	 collected	 through	 the	national	
Treatment	 Demand	 Indicator	 system.	 Such	 systems	
collect	data	on	the	drug	use	and	demographic	charac-
teristics	of	all	drug	users	entering	into	drug	treatment	
programmes	 [18].	 All	 EU	 Member	 States	 have	 such	 a	
system	 to	 collect	 data	 from	 the	 clinical	 assessments	
of	those	presenting	for	treatment,	but	most	do	not	use	
it	 to	 collect	 information	 on	 risk	 behaviours	 related	 to	
HIV	and	other	infections.	Five	countries	reported	using	
their	 national	 Treatment	 Demand	 Indicator	 system	 for	
collecting	 national	 HIV-related	 behavioural	 surveil-
lance	 data	 (France,	 Ireland,	 Luxemburg,	 Slovenia	 and	
Spain)	and	in	two,	it	was	the	only	system	used	(Ireland	
and	Luxembourg).
Of	 the	 29	 behavioural	 surveillance	 studies,	 27	 used	
a	 repeated	 survey	 and	 two	 used	 cohorts	 (Table	 1);	
23	 studies	 were	 still	 ongoing.	 They	 were	 reported	
by	 12	 countries	 (Belgium,	 Estonia,	 Finland,	 France,	
Greece,	 Lithuania,	 Netherlands,	 Poland,	 Slovenia,	
Spain,	 Switzerland	 and	 United	 Kingdom).	 Among	 the	
studies,	 19	 used	 face-to-face	 interviewing	 and	 eight	
subject-completed	 paper	 questionnaires;	 for	 one,	 the	
method	 was	 stated	 ‘other’	 and	 for	 one,	 the	 method	
was	 not	 reported	 (Table	 1).	 Annual	 samples	 sizes	
ranged	 from	 100	 to	 over	 3,000	 (mean:	 1,107;	median:	
400).	The	vast	majority	of	the	repeated	surveys	(21/27)	
recruited	 IDUs;	 however,	 in	 three	 countries	 (France,	
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Netherlands	 and	Spain),	 problem	drug	 users	 (not	 just	
IDUs)	were	recruited.	Of	the	27	studies	using	repeated	
surveys,	 10	 had	 national	 coverage,	 10	 covered	 one	
region	 or	 selected	 regions,	 and	 seven	 were	 local.	
Seven	 countries	 had	 one	 or	 more	 repeated	 surveys	
with	national	coverage	(Table	1).
Seven	 countries	 had	 used	 two	 or	 more	 repeated	 sur-
veys	or	cohorts	 for	behavioural	surveillance	(Belgium,	
Estonia,	 France,	 Lithuania,	 Netherlands,	 Spain	 and	
United	 Kingdom),	 with	 different	 geographical	 cover-
age,	 target	 populations,	 and/or	 settings	 used	 within	
the	countries.	
Topics covered by the behavioural 
surveillance studies
The	 topics	 covered	 by	 data	 collected	 in	 the	 behav-
ioural	surveillance	studies	focused	on	drug	use,	inject-
ing	 practice,	 HIV	 and	 hepatitis	 C	 testing,	 and	 access	
to	 healthcare.	 The	main	 topics	 covered	 in	 the	 studies	
are	 summarised	 in	 Table	 2.	 The	 most	 commonly	 col-
lected	 information	 related	 to	 drug	 use	 and	 the	 shar-
ing	of	injecting	equipment,	with	16	countries	reporting	
that	data	were	collected	on	these	through	behavioural	
surveillance	 studies.	 A	 total	 of	 14	 countries	 reported	
collecting	 information	 related	 to	 HIV,	 hepatitis	 B	 or	
hepatitis	 C	 testing	 or	 status,	 and	 information	 related	
to	 healthcare	 usage	 by	 IDUs.	 Information	 on	 IDU	
knowledge	 and	 attitudes	 was	 collected	 by	 only	 eight	
countries.	
Table 2
Topics most frequently covered in the injecting drug users 
behavioural surveillance studiesa, EU and EFTA countries, 
reported in 2008 by 17 countries
Topic
Number of 
countries 
reporting use 
Sexual	relationships	and	sexual	partners
Types	of	partners/relationships	
(e.g.	regular	partner,	casual	partners)	 11
Sexual	activity	and	lifestyle
Recourse	to	prostitution	(as	sex	worker) 11
Exposure	to	risk	of	infection
Condom	use	at	last	intercourse 11
Condom	use	with	different	types	of	partners	 12
HIV	and	other	sexually	transmitted	infections
HIV	testing 14
Result	of	HIV	test	(self-reported) 11
Result	of	HIV	test	(measured) 12
Hepatitis	B	status	(self-reported) 10
Hepatitis	B	status	(measured) 11
Hepatitis	B	vaccine	(self-report	or	measured) 13
Hepatitis	C	testing 13
Hepatitis	C	status	(self-report	or	measured) 14
Drugs	and	substance	use
Types	of	drugs	consumed 16
Injecting	drug	use 16
Non-injecting	drug	use	 16
Sharing	of	needles	and	syringes 16
Sharing	of	other	injection	material 16
Health	and	access	to	care
Drug	substitution	treatment	(e.g.	methadone) 14
Socio-demographic	characteristics
Education	 12
Employment 12
Imprisonment 12
Housing	conditions 12
Sources	of	income	(work,	drug	dealing,	
pension,	welfare,	prostitution) 11
EFTA:	European	Free	Trade	Association;	EU:	European	Union.
a	 Studies	using	either	a	repeated	survey,	cohort	or	the	Treatment	
Demand	Indicator	system.
Box 1
Behavioural indicators among injecting drug users, EU 
and EFTA countries, reported in 2008 by 8 countries
Eight	of	the	16	countries	with	behavioural	surveillance	
studiesa	reporting	having	national	indicators.
Countries	using	each	indicator	are	listed,	with	the	recall	
period	they	use	(where	known).
Sharing needles and/or syringes
•	 Belgium:	not	known
•	 Slovenia:	last	month	and	last	time
•	 Switzerland:	borrowing	and	passing	on,	last	month	and	last	
six	months
•	 United	Kingdom:	last	month	and	last	six	months
Sharing other injecting equipment
•	 Belgium:	not	known
•	 Slovenia:	last	month	and	last	time
Sharing any injecting equipment
•	 Finland:	last	month
•	 France:	borrowing	only,	last	30	days
•	 Luxembourg:	borrowing	only,	last	30	days
•	 Poland:	last	month,	last	year,	ever
•	 United	Kingdom:	last	month	and	last	six	months
Uptake of voluntary confidential HIV test
•	 Belgium:	last	year
•	 Luxembourg:	last	five	months	and	ever	tested
•	 Poland:	last	year	and	ever	tested
•	 Switzerland:	lifetime
•	 United	Kingdom:	lifetime
Uptake of voluntary confidential hepatitis C virus test
•	 Belgium:	not	known
•	 Luxembourg:	last	five	months	and	ever	tested
•	 Poland:	last	year	and	ever	tested
•	 Switzerland:	lifetime
•	 United	Kingdom:	lifetime
Age first injected
•	 Belgium
•	 Finland
Condom use
•	 Finland:	last	six	months	(regular	or	casual	partners)
•	 Luxembourg:	last	time	(by	gender)	
•	 Slovenia:	last	time
•	 Switzerland:	last	time,	last	six	months	with	regular	and	
casual	partners
EFTA:	European	Free	Trade	Association;	EU:	European	Union.
a	 Studies	using	either	a	repeated	survey,	cohort	or	the	Treatment	
Demand	Indicator	system.
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Behavioural Indicators 
Eight	 (of	 16)	 countries	 reported	 having	 behavioural	
indicators	 related	 to	 the	 monitoring	 of	 the	 impact	 of	
programmes	to	reduce	HIV	and	other	infections	among	
IDUs.	 The	 seven	 behavioural	 indicators	 that	 were	
reported	by	more	 than	one	 country,	with	 the	 country-
specific	recall	periods	used,	are	shown	in	Box	1.	Three	
indicators	were	each	reported	by	five	countries:	volun-
tary	confidential	testing	for	HIV;	voluntary	confidential	
testing	 for	 hepatitis	 C;	 and	 the	 sharing	 of	 any	 inject-
ing	equipment	in	the	last	month	or	30	days	There	were,	
however,	 variations	 in	 the	 recall	 periods	 for	 the	 test-
ing	 indicators,	 with	 ‘ever	 tested’	 being	 used	 by	 four	
countries.	
One-off behavioural surveys 
In	 total,	 20	 one-off	 surveys	 had	 been	 used	 to	 collect	
behavioural	 data	 in	 seven	 countries	 (France,	 Ireland,	
Latvia,	 Lithuania,	 Luxembourg,	 Sweden	 and	 United	
Kingdom;	Table	3).	In	one	country,	Latvia,	these	formed	
a	series	of	surveys	that	provided	data	over	time;	though	
these	 surveys	 had	 varied	methodologically	 from	 year	
to	year,	they	resulted	in	an	informal	surveillance	struc-
ture.	 In	 the	 other	 countries	with	multiple	 one-off	 sur-
veys,	these	were	not	comparable	to	each	other,	as	they	
had,	for	example,	recruited	IDUs	from	different	areas	or	
had	different	inclusion	criteria.	As	with	the	behavioural	
surveillance	studies	that	used	repeated	surveys,	these	
one-off	surveys	had	used	a	wide	range	of	methods	and	
varied	 in	 sample	 size	 (from	 194	 to	 2,740;	mean:	 676;	
median:	463).	They	also	included	surveys	of	prisoners	
(one	survey)	and	other	drug	users	(one	of	problem	drug	
users	 and	one	of	 techno	 events	 and	 clubbing	popula-
tion)	as	well	as	IDUs.	Of	the	one-off	surveys	reported,	
nine	had	national	coverage,	two	covered	only	a	region	
or	selected	regions,	eight	were	 local,	and	for	one,	 the	
geographical	coverage	was	not	given.
Five	 countries	 reported	 both	 behavioural	 surveillance	
studies	and	one-off	surveys.	The	approaches	used	for	
the	 behavioural	 surveillance	 studies	 in	 these	 coun-
tries	 varied:	 three	 collected	 data	 through	 repeated	
surveys	 and	 three	 through	 their	 Treatment	 Demand	
Indicator	systems	(one	country,	France,	had	used	both	
approaches).	
Sampling approaches
In	the	absence	of	a	sampling	frame	for	 IDUs,	all	coun-
tries	 had	 used	 convenience	 sampling	 frameworks	 to	
recruit	IDUs	for	one-off	surveys	or	for	the	repeated	sur-
veys	used	in	behavioural	surveillance	studies	(Tables	1	
and	3).	Most	 countries	 used	 services	–	 typically	 easy	
to	access	(i.e.	low-threshold)	ones,	such	as	NSPs	–	as	
a	 setting	 for	 recruiting	 and	 surveying	 IDUs;	 however,	
four	countries	had	used	respondent-driven	sampling	to	
recruit	from	communities.	
Discussion and conclusion
Mapping	 behavioural	 surveillance	 in	 2008	 related	 to	
HIV	and	other	STIs	among	IDUs	indicated	that	16	coun-
tries	 had	 conducted	 behavioural	 surveillance	 studies	
for	 this	 subpopulation.	 A	 further	 two	 countries	 had	
undertaken	one-off	behavioural	surveys;	and	in	one	of	
these	countries,	these	surveys	resulted	in	an	 informal	
surveillance	structure.	More	countries	had	behavioural	
surveillance	studies	 for	 IDUs	than	 for	any	of	 the	other	
population	 groups:	 14	 countries	 for	 MSM;	 13	 for	 the	
general	 population;	 13	 for	 young	 people	 (youth);	 nine	
for	people	 living	with	HIV/AIDS;	nine	 for	clients	of	STI	
clinics;	six	for	sex	workers;	and	three	for	migrant	pop-
ulations	 [16,17,19].	 A	 number	 of	 these	 countries	 have,	
or	 have	 had,	 more	 than	 one	 behavioural	 surveillance	
study	 among	 IDUs.	 Most	 often	 the	 population	 group	
with	the	most	studies	 in	a	country	was	also	 IDUs	[16].	
While	behavioural	surveillance	related	to	HIV	was	more	
established	 among	 IDUs	 than	 among	 other	 popula-
tions,	two	fifths	(n=10)	of	the	28	countries	responding	
to	 the	 survey	 reported	having	 no	 behavioural	 surveil-
lance-related	activities	among	IDUs.
It	is	important	to	consider	the	limitations	of	our	study.	
The	 information	 collected	 was	 self-reported	 and	 the	
responses	varied	greatly	in	the	level	of	detail	provided.	
The	 questionnaires	 were	 sent	 to	 the	 ECDC	 national	
contact	 person	 for	 HIV	 biological	 surveillance	 in	 each	
country	as	there	is	no	specific	ECDC	contact	person	for	
behavioural	 surveillance.	 This	 person	 may	 thus	 have	
been	 unaware	 of	 the	 existence	 of	 surveys,	 whether	
organised	 or	 not	 into	 a	 behavioural	 surveillance	 sys-
tem.	 However,	 for	 the	 questionnaire	 on	 behavioural	
surveillance	 among	 IDUs,	 liaison	 with	 the	 EMCDDA	
National	 Focal	 Point	 in	 each	 EU	 country	 and	 Norway	
was	 encouraged.	 This	 should	 have	 minimised	 under-
reporting	 of	 existing	 studies	 of	 IDUs.	 The	 draft	 map-
ping	 report	 [16]	 was	 also	 circulated	 to	 countries	 for	
validation,	 so	 providing	 an	 opportunity	 to	 both	make	
corrections	 and	 review	 its	 completeness.	 The	 data	
collected	 here	 are	 likely	 to	 be	 robust;	 however,	 three	
countries	 did	 not	 return	 the	 questionnaire	 on	 behav-
ioural	surveillance	among	 IDUs,	and	two	of	 those	that	
did	 return	 the	questionnaire	and	who	reported	having	
behavioural	surveillance	studies	among	IDUs	provided	
no	 details.	 While	 the	 response	 and	 completion	 rates	
were	 high	 (90%	 and	 93%,	 respectively),	 it	 cannot	 be	
assumed	that	the	non-responding	countries	and	those	
not	providing	information	are	similar	to	those	who	did.	
Our	 findings	 should	 thus	be	generalised	 to	 the	whole	
of	the	EU/EFTA	area	cautiously.
The	 fact	 that	more	countries	had	ongoing	behavioural	
surveillance	among	IDUs	than	in	the	other	groups	stud-
ied	 might	 reflect,	 in	 part	 at	 least,	 the	 impact	 of	 the	
EMCDDA-established	 key	 indicator	 on	 drug-related	
infectious	diseases.	Following	its	inauguration	in	1995,	
EMCDDA	set	up	a	standardised	system	 to	collect	data	
for	 this	 key	 indicator	 [3].	 This	 collates	 the	 findings	
from	HIV,	hepatitis	C	and	hepatitis	B	prevalence	stud-
ies	 among	 IDUs	and	has	more	 recently	 started	 to	 col-
lect	behavioural	data	[3].	In	response	to	HIV	in	the	late	
1980s	 and	 early	 1990s,	 a	 number	 of	 countries	 estab-
lished	 sero-surveillance	 studies	 among	 IDUs	 to	 over-
come	the	potential	biases	in	monitoring	HIV	prevalence	
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among	marginalised	populations	such	as	IDUs	through	
diagnostic	 testing	 data.	 These	 studies,	 to	 maximise	
their	 public	 health	 utility,	 have	 also	 collected	 behav-
ioural	data.	Such	 combined	sero-behavioural	 systems	
have	been	established	in	number	of	EU	Member	States	
over	the	last	25	years,	for	example,	Spain	(in	Catalonia)	
[20],	Estonia	[21]	and	United	Kingdom	(England,	Wales	
and	 Northern	 Ireland)	 [22].	 Through	 its	 drug-related	
infectious	 diseases	 key	 indicator,	 the	 EMCDDA	 has	
encouraged	 the	 maintenance	 and	 continued	 develop-
ment	of	such	studies	across	the	EU.
Undertaking	surveys	among	IDUs	presents	a	number	of	
substantial	 practical	 difficulties.	 In	 particular,	 due	 to	
the	illicit	nature	of	drug	injecting	and	the	high	levels	of	
marginalisation	and	associated	stigma,	accessing	pop-
ulations	who	inject	drugs	can	be	difficult,	and	there	is,	
of	 course,	 no	population-based	 sampling	 frame.	 Thus	
surveys	 of	 IDUs	 typically	 use	 accessibility	 sampling	
approaches	 [11,23],	either	 to	access	 individuals	 in	 the	
community	 or	 through	 the	 services	 provided	 to	 them.	
This	need	 to	use	convenience	sampling	approaches	 is	
reflected	in	the	range	of	methods	used	to	collect	behav-
ioural	 data.	 These	 approaches	 ranged	 from	 collecting	
data	 from	 the	 clients	 of	 addiction	 treatment	 services	
using	the	Treatment	Demand	Indicator	system,	through	
the	 purposive	 sampling	 of	 individuals	 in	 contact	with	
services	 provided	 to	 drug	 users	 (such	 as	 NSPs,	 OST,	
drop-in	 centres	 and	 outreach),	 to	 community-based	
recruitment,	 including	 the	 use	 of	 respondent-driven	
sampling	[23].	Sampling	through	specialist	services	for	
drug	users	(such	as	services	providing	NSPs	and	OST)	
was	 the	most	widely	used	approach,	probably	 reflect-
ing	the	extensive	provision	of	a	range	of	such	services	
in	many	European	countries	[4].	
In	most	countries	with	behavioural	surveillance	studies	
of	IDUs,	these	were	being	conducted	annually	or	at	reg-
ular	intervals,	indicating	that	these	systems	were	prob-
ably	routine	surveillance	activities.	Routine	surveillance	
of	risk	among	IDUs	is	important,	considering	the	poten-
tial	for	HIV	to	spread	very	rapidly	through	injecting	drug	
use	 [11].	 The	samples	sizes	used	 in	 the	surveys	varied	
greatly,	with	the	largest	samples	being	about	30	times	
larger	than	the	smallest.	However,	in	part	this	variation	
will	 reflect	 the	 different	 population	 sizes	 of	 the	 coun-
tries	and	also	what	is	known	about	the	extent	of	inject-
ing	drug	use	in	each	country.	 It	 is	 likely	that	the	range	
of	sampling	approaches	used	reflects	what	is	appropri-
ate,	considering	the	local	epidemics	of	drug	use	and	the	
responses	to	these	and,	of	course,	the	resources	avail-
able	for	surveillance	in	each	country.	The	systems	thus	
took	 a	 range	 of	 forms,	 used	 a	 variety	 of	 recruitment	
approaches	 and	 settings,	 and	 varied	 greatly	 in	 size.	
These	 variations	 probably	 reflect	 a	 wide	 range	 in	 the	
quality,	 robustness	 and	 sustainability	 of	 the	 systems,	
although	these	cannot	be	objectively	assessed	through	
a	mapping	exercise	of	this	kind.	
Examination	 of	 the	 topics	 covered	 in	 the	 behavioural	
surveillance	 studies	 among	 IDUs	 indicates	 that	 a	
wide	 range	 of	 topics	 were	 addressed.	 The	main	 ones	
(reported	 in	 at	 least	 two	 thirds	 of	 the	 countries	 with	
behavioural	surveillance	studies)	concerned	drug	use,	
injecting	risks,	HIV	and	hepatitis	C	testing,	hepatitis	B	
vaccination	 and	 sexual	 risks.	 This	 list	 of	 topics	 is	 not	
surprising	 considering	 the	 ease	 with	 which	 HIV	 and	
hepatitis	 B	 and	 C	 viruses	 can	 be	 transmitted	 through	
unsafe	 injecting	 practices,	 but	 the	 lack	 of	 sexual	 risk	
information	 in	 a	 third	 of	 the	 countries	 is	 of	 concern,	
given	 that	 STIs,	 HIV	 and	 hepatitis	 B	 virus	 are	 readily	
transmitted	through	unprotected	sexual	intercourse.
Almost	 half	 of	 the	 countries	with	 behavioural	 surveil-
lance	studies	had	identified	key	behavioural	indicators	
that	 they	 specifically	 used	 for	 monitoring	 purposes.	
The	most	common	key	indicators	focused	on	voluntary	
confidential	 testing	 for	 HIV	 and	 hepatitis	 C,	 and	 the	
sharing	 of	 injecting	 equipment.	 Half	 of	 the	 countries	
with	 key	 indicators	had	 included	 condom	use	as	 indi-
cator.	 The	 set	 of	 indicators	 suggested	 by	 ECDC	 after	
consultation	in	the	2009	expert	meeting	[16]	are	shown	
in	Box	2.	
These	indicators	include	those	that	are	most	frequently	
used	 in	 the	 eight	 countries	 with	 key	 indicators	 (i.e.	
testing	 for	 HIV,	 testing	 for	 hepatitis	 C	 virus	 and	 shar-
ing	 injecting	 equipment)	 and	 they	 also	 reflect	 the	
Box 2
Suggested indicators for use with injecting drug users, EU 
and EFTA countries 
Transversal indicators (those common with other population 
groups)a
Main indicators:
•	 condom	use	at	last	sexual	intercourseb
•	 HIV	testing	and	test	result	(reported	or	measured)b
Also where appropriate:
•	 number	of	sexual	partners	in	the	last	12	months
•	 involvement	in	sex	work	(as	client)
Suggested IDU-specific indicators
Main indicators:
•	 needles	and	syringe	sharingb,c
•	 injecting	frequencyb,c
•	 number	of	new	needles/syringes	obtainedb,c
•	 recently	received	a	substitute	drugb,c
Additional indicators:
•	 hepatitis	C	testing	(same	format	as	for	HIV	testing	
transversal	indicator)a
•	 years	since	first	injectedb
•	 having	been	paid	for	sexb
Other possible options include:
•	 number	of	sharing	partnersb,c
•	 ever	injected	in	prison
EFTA:	European	Free	Trade	Association;	EU:	European	Union.
a	 Source:	[16].	
b	 Indicators	for	which	the	European	Monitoring	Centre	for	Drugs	
and	Drug	Addiction	(EMCDDA)	is	collecting	behavioural	data.	
c	 Recall	periods	for	these	indicators	need	to	be	agreed,	although	
the	mapping	exercise	indicates	that	the	last	month	(last	28	or	
30	days)	is	commonly	used	for	these,	and	would	probably	be	
an	appropriate	period	where	injecting	is	a	regular	event	(e.g.	
from	several	times	a	week	to	daily),	but	may	be	too	short	where	
injecting	is	less	frequent.
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topics	 covered	 in	most	 behavioural	 surveillance	 stud-
ies.	While	 further	consultation	 is	needed	on	the	recall	
periods	and	 the	specific	definitions	 for	some	of	 these	
indicators,	 the	 studies	 do	 provide	 a	 framework	 from	
which	 a	 core	 set	 of	 behavioural	 indicators	 for	 IDUs	
could	 be	 established.	 The	 adoption	 of	 a	 core	 set	 of	
indicators,	 and	 their	 incorporation	 in	 national	 behav-
ioural	 surveillance	 studies	 for	 IDUs,	would	 then	 allow	
comparisons	 of	 behavioural	 surveillance	 data	 across	
countries.	 This	 currently	 cannot	be	done	 robustly	due	
to	 the	 wide	 range	 of	 different	 indicators	 being	 used	
across	the	EU	and	EFTA.
Behavioural	surveillance	was,	in	2008,	more	frequently	
reported	among	IDUs	than	in	other	subpopulations	(fol-
lowed	closely	by	MSM,	general	population	and	youth)	
[16];	 however,	 10	 of	 the	 28	 of	 the	 countries	 respond-
ing	 reported	no	behavioural	surveillance	among	 IDUs.	
The	approach	used	here,	a	mapping	survey,	may	have	
resulted	 in	under-reporting	of	 surveys,	 particularly	 as	
not	 all	 countries	 replied,	 and	 so	 the	 findings	 should	
be	treated	cautiously.	Even	so,	 the	diversity	of	 indica-
tors	 found	 indicates	a	need	 to	harmonise	behavioural	
surveillance	 indicators	 among	 IDUs	 across	 European	
countries,	and	this	should	consider	international	guid-
ance	[24]	when	developing	any	indicators.	To	this	end,	
EMCDDA,	 in	 consultation	with	 ECDC	 and	 international	
experts,	 is	 currently	 finalising	 its	 protocol	 for	 collect-
ing	 data,	 including	 behavioural	 data,	 on	 drug-related	
infectious	diseases	among	IDUs.
The ECDC HIV and STI Behavioural Surveillance 
Mapping Group
The	 full	 report	 (ECDC	 Technical	 Report	 Mapping	 of	 HIV/STI	
behavioural	 surveillance	 in	 Europe	 [16])	was	 commissioned	
by	 ECDC,	 coordinated	 by	Marita	 van	 de	 Laar	 and	 produced	
by	the	Institute	for	Social	and	Preventive	Medicine	(IUMSP),	
University	of	 Lausanne,	Switzerland,	working	with	an	 inter-
national	team	of	experts	listed	below.	The	main	role	of	each	
person	 is	 included	 in	 parentheses;	 each	 expert	 focused	 on	
one	population	group.
Françoise	 Dubois-Arber,	 Institute	 for	 Social	 and	 Preventive	
Medicine	 (IUMSP),	 Lausanne,	 Switzerland	 (team	 leader,	
youth);	Brenda	Spencer,	IUMSP,	Lausanne,	Switzerland	(gen-
eral	population);	Vivian	Hope,	London	School	of	Hygiene	and	
Tropical	Medicine,	 United	 Kingdom	 (IDUs);	 Jonathan	 Elford,	
City	University,	London,	United	Kingdom	(MSM);	France	Lert,	
Institut	 national	 de	 la	 santé	 et	 de	 la	 recherché	 médicale,	
France	 (people	 living	 with	 HIV/AIDS);	 Helen	Ward,	 Imperial	
College,	 London,	 United	 Kingdom	 (sex	 workers);	 Nicola	
Low,	 Institute	 for	 Social	 and	 Preventive	 Medicine,	 Berne,	
Switzerland	(STI	clinic	patients);	Mary	Haour-Knipe,	freelance	
consultant,	 formerly	with	 the	 International	Organization	 for	
Migration	 (migrants	 and	 ethnic	 minorities);	 André	 Jeannin,	
IUMSP,	Lausanne,	Switzerland	(organisation	of	survey);	Jean-
Pierre	 Gervasoni,	 IUMSP,	 Lausanne,	 Switzerland	 (organi-
sation	 of	 survey);	 Marie-Jeanne	 Pellaz,	 IUMSP,	 Lausanne,	
Switzerland	 (secretarial	 assistance);	 Bertrand	Graz,	 IUMSP,	
Lausanne,	 Switzerland	 (literature	 review);	 Marita	 van	 de	
Laar,	ECDC,	Stockholm,	Sweden	(coordinator).
References
1.	 Wiessing	L,	Ncube	F,	Hedrich	D,	Griffiths	P,	Hope	V,	Gill	N,	
et	al.	Surveillance	of	infectious	diseases	in	IDUs	across	
the	EU:	information	from	the	EU	expert	network.	Euro	
Surveill.	2004;8(4):pii=2368.	Available	from:	http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=2368	
2.	 Health	Protection	Agency,	Health	Protection	Scotland,	National	
Public	Health	Service	for	Wales,	CDSC	Northern	Ireland,	
CRDHB.	Shooting	up:	infections	among	injecting	drug	users	in	
the	United	Kingdom	2008.	London:	Health	Protection	Agency;	
October	2009.	Available	from:	http://www.hpa.org.uk/web/
HPAwebFile/HPAweb_C/1254510653792	
3.	 European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	
(EMCDDA).	Drug-related	infectious	diseases.	Lisbon:	EMCDDA.	
[Accessed	9	Jul	2010].	Available	from:	http://www.emcdda.
europa.eu/themes/key-indicators/drid	
4.	 European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	
(EMCDDA).	Trends	in	injecting	drug	use	in	Europe.	Selected	
Issue	2010.	Lisbon:	EMCDDA:	2010.	Available	from:	http://
www.emcdda.europa.eu/publications/selected-issues/
injecting	
5.	 Hedrich	D,	Pirona	A.	Wiessing	L.	From	margin	to	mainstream:	
the	evolution	of	harm	reduction	responses	to	problem	drug	
use	in	Europe.	Drugs:	Education,	Prevention,	and	Policy.	
2008;15(6):503-17.	Available	from:	http://informahealthcare.
com/doi/abs/10.1080/09687630802227673	
6.	 Wodak	A,	Cooney	A.	Do	needle	syringe	programs	reduce	
HIV	infection	among	injecting	drug	users:	a	comprehensive	
review	of	the	international	evidence.	Subst	Use	Misuse.	
2006;41(6-7):777-813.	
7.	 World	Health	Organization	(WHO).	Effectiveness	of	sterile	
needle	and	syringe	programming	in	reducing	HIV/AIDS	among	
injecting	drug	users.	(Evidence	for	action	technical	papers).	
Geneva:	WHO;	2004.	Available	from:	http://www.who.int/hiv/
pub/prev_care/effectivenesssterileneedle.pdf	
8.	 Vickerman	P,	Hickman	M,	Judd	A.	Modelling	the	impact	on	
hepatitis	C	transmission	of	reducing	syringe	sharing:	London	
case	study.	Int	J	Epidemiol.	2007;36(2):396-405.	
9.	 Van	Den	Berg	C,	Smit	C,	Van	Brussel	G,	Coutinho	R,	Prins	
M;	Amsterdam	Cohort.	Full	participation	in	harm	reduction	
programmes	is	associated	with	decreased	risk	for	human	
immunodeficiency	virus	and	hepatitis	C	virus:	evidence	from	
the	Amsterdam	Cohort	Studies	among	drug	users.	Addiction.	
2007;102(9):1454-62.	
10.	 Hope	VD,	Hickman	M,	Ngui	SL,	Jones	S,	Telfer	M,	Bizzarri	
M,	et	al	Measuring	the	incidence,	prevalence	and	genetic	
relatedness	of	hepatitis	C	infections	among	a	community	
recruited	sample	of	injecting	drug	users,	using	dried	blood	
spots.	J	Viral	Hepat.	2011;18(4):262-70.	
11.	 Des	Jarlais	DC,	Dehne	K,	Casabona	J.	HIV	surveillance	among	
injecting	drug	users.	AIDS.	2001;15	Supplement	3:S13-22.	
12.	 Joint	United	Nations	Programme	on	HIV/AIDS	(UNAIDS),	
World	Health	Organization	(WHO).	UNAIDS/WHO	Working	
Group	on	Global	HIV/AIDS	and	STI	Surveillance.	Guidelines	
for	second	generation	HIV	surveillance.	Geneva:	UNAIDS	
and	WHO;	2000.	WHO/CDS/CSR/EDC/2000;	UNAIDS/00.03E.	
Available	from:	http://data.unaids.org/publications/irc-pub01/
jc370-2ndgeneration_en.pdf	
13.	 European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	
(EMCDDA).	An	overview	of	the	drug-related	infectious	diseases	
(DRID)	key	indicator.	Lisbon:	EMCDDA;	2009.	Available	from:	
http://www.emcdda.europa.eu/publications/methods/
drid-overview	
14.	 European	Centre	for	the	Epidemiological	Monitoring	of	AIDS	
(EuroHIV).	HIV/AIDS	surveillance	in	Europe.	Mid-year	report	
2001.	No.	65.	Saint-Maurice:	Institut	de	Veille	Sanitaire;	2001.	
Available	from:	http://www.ecdc.europa.eu/en/activities/
surveillance/hiv/Documents/report_eurohiv_midyear_2001.pdf	
15.	 European	Centre	for	the	Epidemiological	Monitoring	of	AIDS	
(EuroHIV).	EuroHIV	2006	survey	on	HIV	and	AIDS	surveillance	
in	the	WHO	European	Region.	Saint-Maurice:	Institut	de	veille	
sanitaire;	2007.	Available	from:	http://www.invs.sante.fr/
publications/2007/eurohiv_2006/HIV_AIDS_Web.pdf	
16.	 European	Centre	for	Disease	Prevention	and	Control.	
Mapping	of	HIV/STI	behavioural	surveillance	in	Europe.	
ECDC	Technical	Report.	Stockholm:	ECDC;	September	2009.	
Available	from:	http://www.ecdc.europa.eu/en/publications/
Publications/0909_TER_Mapping_of_HIV_STI_Behavioural_
Surveillance_in_Europe.pdf	
17.	 Dubois-Arber	F,	Jeannin	A,	Spencer	B,	Gervasoni	JP,	Graz	B,	
Elford	J,	et	al.	Mapping	HIV/STI	behavioural	surveillance	in	
Europe.	BMC	Infect	Dis.	2010;10:290.	
9www.eurosurveillance.org
18.	 European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	
(EMCDDA).	An	overview	of	the	treatment	demand	key	indicator	
(TDI).	Lisbon:	EMCDDA;	2009.	Available	from:	http://www.
emcdda.europa.eu/publications/methods/tdi-overview	
19.	 Elford	J,	Jeannin	A,	Spencer	B,	Gervasoni	JP,	van	de	Laar	MJ,	
Dubois-Arber	F;	et	al..	HIV	and	STI	behavioural	surveillance	
among	men	who	have	sex	with	men	in	Europe.	Euro	Surveill.	
2009;14(47):pii=19414.	Available	from:	http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=19414	
20.	Centre	d’Estudis	Epidemiològics	sobre	les	Infeccions	de	
Transmissió	Sexual	i	Sida	de	Catalunya	(CEEISCAT).	SIVES	
2008	:	integrated	Aids/HIV/STI	surveillance	system	of	
Catalonia	(SIVES):	biennial	epidemiological	report	.	Barcelona:	
Generalitat	de	Catalunya,	Departament	de	Salut;	2008.	
(Technical	document	CEEISCAT,	19).	Available	from:	http://
www.ceescat.org/Documents_Ing1.htm	
21.	 Vorobjov	S,	Uusküla	A,	Abel-Ollo	K,	Talu	A,	Rüütel	K,	Des	
Jarlais	DC.	Comparison	of	injecting	drug	users	who	obtain	
syringes	from	pharmacies	and	syringe	exchange	programs	in	
Tallinn,	Estonia.	Harm	Reduct	J.	2009;6:3.	
22.	Hope	VD,	Judd	A,	Hickman	M,	Sutton	A,	Stimson	GV,	Parry	JV,	
et	al.	HIV	prevalence	among	injecting	drug	users	in	England	
and	Wales	1990	to	2003:	evidence	for	increased	transmission	
in	recent	years.	AIDS.	2005;19(11):1207-14.	
23.	Magnani	R,	Sabin	K,	Saidel	T,	Heckathorn	D.	Review	of	
sampling	hard-to-reach	and	hidden	populations	for	HIV	
surveillance.	AIDS.	2005;19	Suppl	2:S67-72.	
24.	World	Health	Organization	(WHO).	WHO,	UNODC,	UNAIDS	
technical	guide	for	countries	to	set	targets	for	universal	access	
to	HIV	prevention,	treatment	and	care	for	injecting	drug	users.	
Geneva:	WHO;	2009.	Available	from:	http://www.unodc.org/
documents/hiv-aids/idu_target_setting_guide.pdf
